These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. Chakder S; Rattan S J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560 [TBL] [Abstract][Full Text] [Related]
5. Pre-clinical study on tumor vasoactive intestinal peptide receptor scintigraphy. Wang X; Zhang M; Yang Z; Lin B; Zhang Q Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):331-4. PubMed ID: 12408757 [TBL] [Abstract][Full Text] [Related]
6. Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors. Cheng D; Yin D; Li G; Wang M; Li S; Zheng M; Cai H; Wang Y Chem Biol Drug Des; 2006 Dec; 68(6):319-25. PubMed ID: 17177894 [TBL] [Abstract][Full Text] [Related]
7. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. Thakur ML; Marcus CS; Saeed S; Pallela V; Minami C; Diggles L; Le Pham H; Ahdoot R; Kalinowski EA J Nucl Med; 2000 Jan; 41(1):107-10. PubMed ID: 10647612 [TBL] [Abstract][Full Text] [Related]
8. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785 [TBL] [Abstract][Full Text] [Related]
9. Radiosynthesis of 18F-(R8,15,21, L17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours. Cheng D; Yin D; Zhang L; Wang M; Li G; Wang Y Nucl Med Commun; 2007 Jun; 28(6):501-6. PubMed ID: 17460542 [TBL] [Abstract][Full Text] [Related]
10. Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Harmar AJ; Sheward WJ; Morrison CF; Waser B; Gugger M; Reubi JC Endocrinology; 2004 Mar; 145(3):1203-10. PubMed ID: 14617572 [TBL] [Abstract][Full Text] [Related]
11. Distribution of VIP binding sites in opossum internal anal sphincter circular smooth muscle. Chakder S; Rattan S J Pharmacol Exp Ther; 1995 Jan; 272(1):385-91. PubMed ID: 7815354 [TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916 [TBL] [Abstract][Full Text] [Related]
14. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. Reubi JC J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054 [TBL] [Abstract][Full Text] [Related]
15. Sandostatin labeled with 99mTc: in vitro stability, in vivo validity and comparison with 111In-DTPA-octreotide. Kolan H; Li J; Thakur ML Pept Res; 1996; 9(3):144-50. PubMed ID: 8875594 [TBL] [Abstract][Full Text] [Related]
16. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198 [TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone (PTH) and PTH-related peptide induce relaxation of smooth muscle cells from guinea pig ileum: interaction with vasoactive intestinal peptide receptors. Botella A; Rekik M; Delvaux M; Davicco MJ; Barlet JP; Frexinos J; Bueno L Endocrinology; 1994 Nov; 135(5):2160-7. PubMed ID: 7525262 [TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting. Rangger C; Helbok A; Ocak M; Radolf T; Andreae F; Virgolini IJ; Von Guggenberg E; Decristoforo C Anticancer Res; 2013 Apr; 33(4):1537-46. PubMed ID: 23564795 [TBL] [Abstract][Full Text] [Related]
19. [A biodistribution experiment on 125 I-VIP in mice]. Zhao Y; Yang J Hua Xi Yi Ke Da Xue Xue Bao; 1998 Sep; 29(3):281-4. PubMed ID: 10684093 [TBL] [Abstract][Full Text] [Related]